Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
* * $MBVX Video Chart 07-24-17 * *
Link to Video - click here to watch the technical chart video
Time for the eagle to put its wings on and fly this baby to the moon.
News! May be a good play today....don't forget to play the MOMO!
Wolf of pennystocks Pump-N-Dump newsletter. Gets paid to pump stocks that are about to get get dumped.
who is wolf?..tyia bro
Another Pump-N-Dump in the works. Wolf got $35,000 to pump this.
Conference call after market closes. Possible trial update and catalyst.
Murocman
In since before the split and uplist I received the same letter, probably the same, from the CEO... it worked I bought more. GLTALs
Got a Pumpy-McDumpy Email Promotion recently. Someone paid $20,000 to pump this.
I believe that MBVX is a great mid to long term play
Will be watching closely after conference
Wow just a 3.78 million shares left in float!!
DMPI (Del Mar Pharma) will be the next to run
HOLD your MBVX and BUY DMPI
KAE
Sorry for your loss.
Had a paid pump out this morning on this. I closed my small position for a tiny loss. Scratch. Glty.
New Investor Presentation
I know it's early in development, but slide #13 is pretty amazing.
Should be well received at Rodman and Renshaw Global Investment Conference next week.
http://www.mabvax.com/resources/MabVax%20Presentation%20for%20Investors%20September%202016.pdf
need to pps stated here, MabVax Therapeutics Holdings Inc. (MBVX)'
is this ah 3-d company ????? 'MabVax Therapeutics Holdings Inc. (MBVX)'
no pps given here/
Nice hints in August 11 10-Q filing that upcoming pr on Phase I trial will be positive
"Of the nine patients who have been dosed to date, five have been treated for three or more months and investigator observations have noted stable disease for a subset of those patients. We are continuing to escalate the drug dose to assess safety and reach an MTD and anticipate initiating the second portion of the trial where our drug is dosed in combination with chemotherapy in the fourth quarter of this year. We expect to have the preliminary results of this clinical trial later in the third quarter in 2016.”
Stable disease in a subset of patients- pancreatic cancer and "stable disease" are not usually found in the same sentence.
Nice summary Lloyd. I hold a small position here which I'll just let it ride into the data. I thought 2 phase I data coming up this quarter. End of sept. Read in the filings. Could be wrong. I sometimes mix up my bios lmao
Pretty good way to structure a RS if your going to do one imho. Warrants exercise $5.55 and & $6.29. OPKO offering/purchase price April 2015 was at $.75 split adjusted $5.55 coincidentally the same price as current warrants. Expecting data in the next quarter. If my numbers are right after the RS OPKO/ Frost own 2,092,702 shares of common and new investors with current offering own 1,127,859. Directors and officers own approx 386,926 shares. There are now total 5,363,198 common. Looks like insiders had a bit of participation in the offering with today's form 4s. Market cap at $27M. Interesting to watch the bid ask spread which has been as wide as 50 cents during the day. Three days on Nasdaq pretty stable price so far. Have to see what the data shows. But with low float, add a bit of volume and these can be fun.
Hmmm, I didn't realize you could do both at the same time. Good to know. Thanks
They did both. $4.80 ish.
Sorry what was the opening price after r/s, not uplisting
Did they perform thier R/S and uplisting simultaneously? And what was the opening price after uplisting?
MBVX moved to the Nasdaq from the OTC:
http://otce.finra.org/DLDeletions
MBVX one for 7.4 reverse split:
http://otce.finra.org/DLSymbolNameChanges
Nice. This will spike IMO.
Market cap after split and Nasdaq up list should be approx $28M and company will have $10M cash. All warrants appear to be exercisable above current prices. 1,559,252 "A" warrants exercise at $5.55 and 1,559,252 "B" warrants at $6.29.
Great thx. It was late lol.
Two preliminary phase I data due by end of Sept. This might have a run here IMO. I've got my tickets.
Total shares originally offered were 1,299,376 @$4.81 proceeds of $6,250,000. It looks like it was increased to 1,559,252 shares offered at $4.81 for total proceeds of $7,500,000. These numbers are after the 1 for 7.4 reverse split. Total shares after split 5,790,032 or 8,908,536 if all warrants are exercised in the future. Nasdaq application was approved so all appears to be a green light to reverse split, close the offering, and begin trading to Nasdaq.
Dang it they upped their offering seems like went from 5 mil to 7.5 mil shares? Amendment to s1 out ah. Am I reading this correctly?
I think that uplisting to NASDAQ is pretty big news. This makes the stock available to mutual funds, ETFs and other institutional investors that are mostly forbidden from investing in OTC securities. I have been waiting for this for a while now. Shareholders also authorized a reverse split in 2015 for this purpose but they didn't pull the trigger on it. The first results on the phase 1 trials are due to be released this quarter also so hopefully that will be the big news to coincide with the uplisting. My fingers are crossed.
The r/s without strong news and financials are not good - the price can come down easily.
Now it depends when they execute r/s -raise new money and give some interim update
With dilution and no new news - the price can slide down post r/s
On free options.....
whats next burp (besides a drink?)
Look at 10-k filed on 30th Jun - item no 2
(This is in the news tab of ihub)
Todays filing are amendments to the 10k already filed and resale of securities - this is the securities /warrants already issued.
This didn't jump out at me in the Prospectus filed, is that where you found it?
Followers
|
57
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1194
|
Created
|
04/12/01
|
Type
|
Free
|
Moderators |
| MabVax Therapeutics Holdings is a clinical-stage biopharmaceutical company focused on discovering and developing innovative vaccine and monoclonal antibody-based therapeutics for the diagnosis and treatment of cancer. We generate our pipeline of antibody-based product candidates from patients who have been vaccinated with propriety vaccines licensed from Memorial Sloan-Kettering Cancer Center, or MSKCC. Our approach of surveying the protective immune response from many patients to identify the ideal monoclonal antibody candidate against a specific target on the surface of a cancer cell is a novel next-generation human antibody technology platform. Our approach to antibody discovery is to seek to identify the antibody candidates with superior performance characteristics while minimizing many of the toxicity and off target binding drawbacks of other discovery technologies. Our lead antibody candidates have been recovered from patients who had substantially better treatment outcomes than almost all other patients in clinical trials we conducted or that were conducted by our partners. Our therapeutic vaccines were developed at MSKCC and are exclusively licensed to us pursuant to agreements with MSKCC in 2008. These vaccines are administered in the adjuvant (period following conventional treatment consisting of watchful waiting) setting and have shown in clinical studies to elicit a protective antibody response. The antibodies are intended to seek out circulating tumor cells and micrometastases (small clusters of cancer cells) to kill them before they can cause cancer recurrence. Our lead cancer vaccines targeting recurrent sarcoma (soft tissue cancer) and ovarian cancer are currently in proof of concept Phase II multi-center clinical trials. Both trials have received substantial federal grant monies to support their development. A vaccine to address the orphan disease neuroblastoma (cancer starting in the adrenal gland of children which may spread to nervous tissue and bone marrow) has completed an initial Phase I trial at MSKCC and is expected be ready for a Phase II trial by early 2015. MSKCC and the Company have completed additional Phase I vaccine clinical trials in melanoma, ovarian cancer, and small cell lung cancer over the last three years.MBVX Intraday Stock Chart
My Stocks Activity For MBVX
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |